5 February 2024 - From 1 February 2024, Australians with advanced melanoma and relapsing-remitting multiple sclerosis will have access to ...
31 January 2024 - NICE has published final evidence-based recommendations on the use of ivosidenib (Tibsovo) for the treatment of ...
31 January 2024 - NICE has published evidence-based recommendations on the use of loncastuximab tesirine (Zynlonta) for the treatment of ...
30 January 2024 - NICE is unable to make a recommendation on the use of treosulphan (Trecondi) in combination with fludarabine ...
25 January 2024 - The outcomes from the December 2023 PBAC intracycle meeting are now available. ...
19 January 2024 - Around 300 people are set to benefit following NICE’s recommendation of talazoparib tosylate for treating a type ...
18 January 2024 - Since July 2023, there has been one in Germany for patients who suffer from acute myeloid leukaemia ...
17 January 2024 - NICE has published evidence-based recommendations on the use of olaparib (Lynparza) in combination with bevacizumab (Avastin) ...
10 January 2024 - NICE has published evidence-based recommendations on the use of durvalumab (Imfinzi) in combination with cisplatin and ...
21 December 2023 - An Auckland man has resorted to treatment for an aggressive bone marrow cancer in Germany after ...
23 December 2023 - An AstraZeneca drug’s listing on the PBS from January 1 will see bills fall massively for people ...
21 December 2023 - Merck and Eisai announce that Keytruda plus Lenvima, is now reimbursed with clinical criteria and conditions ...
13 December 2023 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) and chemotherapy with or ...
12 December 2023 - PHARMAC is seeking feedback on a proposal to fund two new treatments for advanced breast cancer and ...
1 December 2023 - Thousands of cancer patients in Australia will benefit from a major change that would see Keytruda offered ...